Use of inhaled imipenem/cilastatin in pediatric patients with cystic fibrosis: A case series
Mycobacterium abscessus is a rapidly-growing, virulent, non-tuberculous mycobacterium that causes progressive inflammatory lung damage and significant decline in lung functionin patients with cystic fibrosis. M. abscessus complex pulmonary infections are notoriously difficult to treat, and while many antibiotics are approved for children, drug allergies or intolerances can prohibit their use. Intravenous imipenem/cilastatin is among the preferred antibiotics for treatment of M. abscessus, however, its use may result in systemic toxicities including hepatic injury and gastrointestinal effects.
Source: Journal of Cystic Fibrosis - Category: Respiratory Medicine Authors: Lee Ann Jones, Lorna Doucette, Elisabeth P. Dellon, Charles R. Esther, Cameron J. McKinzie Source Type: research
More News: Allergy | Allergy & Immunology | Children | Cystic Fibrosis | Gastroenterology | Pediatrics | Respiratory Medicine | Toxicology